Imre Kovesdi
Imre Kovesdi is an expert in Allergy at Mo Sci Corporation (United States) (United States). Imre Kovesdi has authored 6 publications, the most recent in 2023. SLR score: 18 (community average: 125). How the SLR is computed.
LeadR Profile
Allergy
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2022 - 2022
Number : 6
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir. PMID 37259374 — infections, herpesvirus 3, human, hepatitis, superinfection, herpes zoster, antiviral agents, vaccines, chickenpox, cells, therapeutics, viruses, infectious bursal disease virus, acyclovir, herpesviridae, rna, double-stranded, sars-cov-2 | Pharmaceuticals (Basel) | 2023 | 5 |
| Regression of Human Breast Carcinoma in Nude Mice after Ad Gene Therapy Is Mediated by Tumor Vascular Endothelial Cell Apoptosis. PMID 36551660 — cells, genes, growth, vascular endothelial growth factor a, receptors, vascular endothelial growth factor, breast neoplasms, adenoviridae, neoplasms, breast, viruses, endothelial cells, therapeutics, apoptosis | Cancers (Basel) | 2022 | 2 |
| Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections. PMID 36275648 — fires, infections, immune system diseases, viruses | Front Immunol | 2022 | 7 |
| An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination. PMID 36176842 — sars-cov-2, hepatitis b virus, interferon-beta, vaccines, pharmaceutical preparations, vaccination, covid-19, herpes zoster, viruses, infectious bursal disease virus, vaccines, attenuated, pandemics, hepatitis viruses, therapeutics, severe acute respiratory syndrome-related coronavirus, antiviral agents, infections, hepatitis, drug candidate | Cureus | 2022 | 7 |
| A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 Patients. PMID 35440336 — cells, smell, safety, pharmaceutical preparations, superinfection, signs and symptoms, covid-19, herpes zoster, viruses, infectious bursal disease virus, therapeutics, infections, hepatitis, virus diseases, drug candidate | Infect Disord Drug Targets | 2022 | 5 |
LeadR Networks
Main global connection map